16 results about "First line therapy" patented technology

The present invention is directed to phage therapy for the treatment and control of bacterial infections, in particular urinary tract infections caused by Escherichia coli. More specifically, the present invention is directed to novel bacteriophage strains, cocktails thereof and variants thereof; and to methods using the same in the treatment, reduction or prevention of bacterial infections. The cocktail is used as a first line treatment against urinary tract infections, in particular in cancer patients, diabetic patients, or patients with a weakened immune system. Disclosed herein is a pharmaceutical composition comprising one or more purified strains of bacteriophage, each purified strain having a genome with at least 98% sequence identity to a nucleotide sequence selected from SEQ. ID No. 1, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 and / or variants thereof. The pharmaceutical composition may also be used in combination with other therapies for urinary tract infections such as antibiotics. The pharmaceutical composition may also be used in a method of diagnosis of the causative agent of a bacterial infection. A bacteriophage comprising at least 95% sequence identity with SEQ. ID No. 1, SEQ ID NO. 5 or SEQ ID NO. 6 is also disclosed.

To provide a method for treating patients having HER2-positive metastatic or locally advanced breast cancer in first-line therapy.SOLUTION: A method comprising administering a therapeutically effective amount of an anti-HER2 maytansinoid conjugate to a patient having breast cancer who has received prior treatment with a taxane.SELECTED DRAWING: None

Use of an anti-B7H3 antibody-drug conjugate, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a metabolite thereof, or a solvate thereof in the preparation of a drug for treating limited-stage or extensive-stage small cell lung cancer (SCLC) that has progressed or relapsed after first-line therapy.

The present disclosure relates to a method of treating highly differentiated G2 or G3 neuroendocrine neoplasms (NET) in a patient in need thereof, the method comprising administering to the patient a treatment of a radioligand therapy (RLT) agent comprising a therapeutically effective dose of a targeted somatostatin receptor (SSTR), in particular [177Lu] Lu-DOTA0-Tyr3-octoic acid, as a first-tier therapy.

This invention relates to the use of inhibitors of IL-6 or IL-6R for treating graft-versus-host disease (GVHD) in a subject, including acute GVHD (aGVHD) or chronic GVHD (cGVHD). In particular, this invention relates to methods of treatment of GVHD in a subject in need thereof, wherein the treatment is a first-line treatment of GVHD, the method comprising a combination therapy of (i) administration to the subject of an antibody or fragment which is capable of inhibiting human IL-6 or human IL-6 receptor; and (ii) administration to the subject of a corticosteroid; wherein the administration of the antibody or fragment is given in a first treatment dose within the period 24 hours before or after initiation of the administration of the corticosteroid.

The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in a treatment-naive subject.

Disclosed in the present invention are a pharmaceutical composition and the use thereof. The pharmaceutical composition of the present invention comprises linperlisib or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, and a chemotherapy regimen drug. The pharmaceutical composition of the present invention is used for the first-line treatment of PTCL. The pharmaceutical composition may provide faster and deeper remission, prolong survival time, have better efficacy and safety in treatment-naive PTCL patients, and can greatly address the unmet clinical needs.

The invention discloses a medicine for resisting intestinal cancer liver metastasis and application thereof, relates to an anti-cancer medicine and application thereof, and is applied to the field of medicine preparation. The invention aims to provide a low-toxicity second-line therapeutic drug after the first-line therapeutic drug for treating liver metastasis of intestinal cancer is resistant. According to the medicine, sunflower stem marrow polysaccharide is combined with intra-tumor rhodopseudomonas palustris, the material basis for inhibiting tumor proliferation is mainly the metabolite 5-aminolevulinic acid of the rhodopseudomonas palustris, and the material basis for inhibiting intestinal cancer from metastasis to liver is mainly the sunflower stem marrow polysaccharide metabolite acetic acid and long-chain fatty acid. The main mechanism for resisting intestinal cancer liver metastasis is cell apoptosis caused by protein such as ROS damaged mitochondrial membrane and the like generated by activation of 5-ALA; the main mechanism of resisting intestinal cancer liver metastasis is that long-chain fatty acid acts on DNA topoisomerase I to influence cell DNA replication. The method is applied to the pharmaceutical field.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses a synergistic effect of combined application of Metrnl protein and a clinical first-line therapeutic drug clopidogrel for treating thrombus, and the Metrnl protein has important significance in the field of thrombotic disease treatment. According to the invention, mice are divided into four groups: a solvent control group, a Metrnl proteome, a clopidogrel group and a drug combination group. A FeCl3 induced thrombus experiment shows that thrombus formation can be inhibited by independently using Metrnl protein and clopidogrel, the thrombus formation inhibition effect is stronger by combined medication, and a synergistic effect is achieved. In addition, in the aspect of untoward effects of bleeding, compared with a clopidogrel single drug group, the risk of bleeding of the drug combination group is not obviously increased. The metrnl protein and clopidogrel are combined to enhance the antithrombotic curative effect without increasing the adverse reaction of bleeding, so that the metrnl protein and clopidogrel have good treatment potential and safety.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The present disclosure provides a method of treating cutaneous melanoma in a subject comprising administering to the subject a composition comprising a heterodimer TCR-anti-CD3 antibody fusion molecule in a dosing regimen wherein the dosing regimen comprises administering: (i) a first dose comprising 2 to 30 [mu] g of the TCR-anti-CD3 antibody fusion molecule, (ii) a second dose comprising from 5 g to 60 g of the TCR-anti-CD3 antibody fusion molecule, and (iii) a maintenance dose comprising from 15 g to 200 g of the TCR-anti-CD3 antibody fusion molecule wherein the maintenance dose is administered in at least three stages wherein the first stage is administered once every 6 to 8 days and the second stage is administered once every 12 to 16 days, and the third stage is administered once every 26 to 30 days, wherein the method is a first-line treatment.

The present invention relates to a system for predicting a primary therapeutic prognosis of a colorectal cancer patient. According to the present invention, the system comprises: a data input unit for receiving clinical information and genetic information of a subject; a feature extraction unit for generating a genomic feature vector reflecting the characteristics of a molecular subtype by selecting and processing genetic features according to a preset molecular subtype reflection criterion among a plurality of pieces of candidate genetic mutation information; and a prognosis prediction unit for predicting a primary therapeutic prognosis of the subject by applying the input clinical information and the generated genomic feature vector to a trained prognosis prediction model, and may further comprise a training unit for training the prognosis prediction model to predict the prognosis of a patient on the basis of pieces of clinical information, pieces of genetic information, and genomic feature vectors of a plurality of patients under preset cohort conditions.

A treatment of lung cancer, particularly small cell lung cancer, in a human subject using an anti-PD-1 antibody and optionally a chemotherapy is provided. In some embodiments, the small cell lung cancer is an advanced (e.g., locally advanced) or diffusive (e.g., stage III or stage IV), non-resectable or metastatic (e.g., with liver, lung or lymph node metastasis, e.g., with 2, 3 or more metastatic sites) lung cancer. In some embodiments, the chemotherapy is carboplatin and / or cis-platinum, and optionally further etoposide. In some embodiments, the SCLC is a small cell carcinoma. In some embodiments, the SCLC is a complex small cell carcinoma. In some embodiments, the treatment is a first-line treatment. In some embodiments, the claimed therapies are effective in the treatment of SCLC. In some embodiments, the human subject is a responder to a treatment by at least one measurement of a response to the treatment.

To provide use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for treating bone and soft tissue sarcomas.SOLUTION: Use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for the treatment of metastatic or locally advanced bone and soft tissue sarcomas that have failed at least first line therapy is provided.SELECTED DRAWING: None

This invention relates to the field of pharmaceutical application technology, specifically a method for preparing and applying a vincristine derivative-antibody conjugate. It involves a composition of a small molecule compound represented by general formula (I), a linker (L), and an antibody (Ab), wherein the small molecule compound is a vincristine derivative, which is conjugated to a targeting antibody via the linker to form an ADC drug with significant antitumor activity. Experiments show that this type of ADC exhibits excellent therapeutic effects in a mouse model of acute myeloid leukemia (AML), with efficacy significantly superior to first-line clinical treatment regimens (such as cytarabine combined with veneclade) and traditional vincristine monotherapy. The ADC provided by this invention has the characteristics of high targeting and low toxicity, providing a new candidate drug for the treatment of malignant tumors such as AML, and possesses significant clinical development value.